{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:53:37Z","timestamp":1783810417998,"version":"3.55.0"},"reference-count":52,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guardant Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We used a real-world database (GuardantINFORMTM) to analyze the treatment choices for patients with mCRC who underwent next-generation sequencing of circulating tumor DNA (ctDNA) using a commercially available test (Guardant360\u00ae) after first- or second-line therapy. From 18,875 patients with claims for CRC, 1064 had confirmed metastatic disease and sufficient histories for analysis (median age 59 years, 44.8% female, 44.5% left-sided). ctDNA was detectable for 997\/1064 (93.7%) patients. Clinically actionable molecular profiles were present for 507\/1064 (47.7%) patients, including those who had not received targeted therapy in the previous line (410\/926, 44.3%). Second- or third-line targeted therapies were administered to 338\/1064 patients (31.8%) and were considered matched for 193\/338 (57.1%) patients. Therapies administered after testing were informed by the ctDNA results in 56.7% of patients overall (603\/1064). Time to treatment discontinuation was most favorable for patients with a clinically actionable ctDNA profile who received matched therapy. This analysis demonstrates the real-world clinical value of plasma-based comprehensive genomic profiling for selecting appropriate molecular-targeted therapies in mCRC patients with disease progression after first- or second-line therapy.<\/jats:p>","DOI":"10.3390\/curroncol29050277","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T21:23:27Z","timestamp":1652131407000},"page":"3433-3448","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database"],"prefix":"10.3390","volume":"29","author":[{"given":"Yoshiaki","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"},{"name":"Translational Research Support Section, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-2384","authenticated-orcid":false,"given":"Steven","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Guardant Health Asia, Middle East, Africa, Inc., Tokyo Port City Takeshiba Office Tower 9th Floor, 1-7-1 Kaigan, Minato-ku, Tokyo 105-7590, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Outcomes and Evidence, Guardant Health, Inc., Redwood City, CA 94063, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Outcomes and Evidence, Guardant Health, Inc., Redwood City, CA 94063, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cca.2020.04.015","article-title":"Recent advances in robotic protein sample preparation for clinical analysis and other biomedical applications","volume":"507","author":"Urban","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: Statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14656566.2021.1982895","article-title":"Pharmacotherapy for unresectable metastatic colorectal cancer","volume":"23","author":"Rogers","year":"2022","journal-title":"Expert Opin. Pharm."},{"key":"ref_4","first-page":"774","article-title":"The emergence of targetable pathways in colorectal cancer","volume":"19","author":"Yu","year":"2021","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"Normanno","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ejca.2015.04.007","article-title":"FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"51","author":"Bokemeyer","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kawazoe, A., Shitara, K., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Fuse, N., Yamanaka, T., and Doi, T. (2015). A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1276-z"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Hitre","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Lenz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18678","DOI":"10.1038\/srep18678","article-title":"Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: Analysis of 1110 cases","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/17410541.6.2.145","article-title":"Toward an individualizing therapy for colorectal cancer: The example of the anti-EGFR monoclonal antibodies","volume":"6","year":"2009","journal-title":"Per. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3748\/wjg.v20.i4.899","article-title":"How to select the optimal treatment for first line metastatic colorectal cancer","volume":"20","author":"Stein","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1158\/1078-0432.CCR-18-3389","article-title":"Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer","volume":"25","author":"Siravegna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: A phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat. Med."},{"key":"ref_19","unstructured":"National Comprehensive Cancer Network (2022, February 17). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer Version 3.2021\u201410 September 2021. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/1078-0432.CCR-19-0823","article-title":"Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies","volume":"25","author":"Parseghian","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.32163","article-title":"Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer","volume":"125","author":"Piawah","year":"2019","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Shuford, R.A., Cairns, A.L., and Moaven, O. (2020). Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers, 12.","DOI":"10.3390\/cancers12113481"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Hurwitz","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000911","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial","volume":"5","author":"Lonardi","year":"2020","journal-title":"ESMO Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"v200","DOI":"10.1093\/annonc\/mdz246.005","article-title":"Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial","volume":"30","author":"Strickler","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.clcc.2020.06.009","article-title":"Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal-Anal Task Forces whitepaper","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_31","unstructured":"Guardant Health Inc. (2022, April 11). Guardant360 CDx Technical Information, D-001590 R3, July 2021. Available online: https:\/\/guardant360cdx.com\/technicalinfo\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"51","author":"Jonker","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00432-018-2747-9","article-title":"Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing","volume":"144","author":"Chang","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1535-7163.MCT-18-0965","article-title":"Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics","volume":"18","author":"Choi","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_37","first-page":"1","article-title":"Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival","volume":"3","author":"Kato","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10408363.2017.1299683","article-title":"Using circulating cell-free DNA to monitor personalized cancer therapy","volume":"54","author":"Oellerich","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational Analysis of Patients With Colorectal Cancer in CALGB\/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","article-title":"Beyond microsatellite testing: Assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition","volume":"9","author":"Fabrizio","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pereira, A.A.L., Morelli, M.P., Overman, M., Kee, B., Fogelman, D., Vilar, E., Shureiqi, I., Raghav, K., Eng, C., and Manuel, S. (2017). Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183949"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1535-7163.MCT-15-0795","article-title":"Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience","volume":"15","author":"Schwaederle","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_49","unstructured":"Inc, M.C. (2022, February 17). KEYTRUDA\u00ae (Pembrolizumab) Injection, for Intravenous Use. Highlights of Prescribing Information, Revised February 2022, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125514s125lbl.pdf."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2159-8290.CD-17-1009","article-title":"Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer","volume":"8","author":"Strickler","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:08:26Z","timestamp":1760137706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050277"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050277","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]}}}